Oral composition

A method for inhibiting plaque accumulation, comprising applying, to the oral cavity, an oral composition comprising the following components (A), (B), (C) and (D):

• (A) 0.01 mass % to 0.5 mass % of a compound represented by the following formula (I):
• wherein R represents an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G represents a galactose residue, E represents a hydrogen atom or a methyl group, m is 0, and n represents an integer of 1 to 3;
• (B) 0.001 mass % to 0.1 mass % of a cationic bactericide selected from the group consisting of cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, chlorhexidine gluconate and chlorhexidine hydrochloride;
• (C) 35 mass % or more of water;
• and
• (D) 0.1 mass % to 1.5 mass % of a nonionic surfactant,
• wherein, in the oral composition, the solubility of the compound represented by formula (I) is enhanced as compared to its solubility in a second composition that is the same as the oral composition except that the second composition lacks component (B), the cationic bactericide, and wherein (A)/(B), the mass ratio of the content of component (A) to the content of component (B), is 0.1 to 100.

A method for inhibiting halitosis, comprising applying, to the oral cavity, an oral composition comprising the following components (A), (B), (C) and (D):

• (A) 0.01 mass % to 0.5 mass % of a compound represented by the following formula (I):
• wherein R represents an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G represents a galactose residue, E represents a hydrogen atom or a methyl group, m is 0, and n represents an integer of 1 to 3;
• (B) 0.001 mass % to 0.1 mass % of a cationic bactericide selected from the group consisting of cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, chlorhexidine gluconate and chlorhexidine hydrochloride;
• and
• (C) 35 mass % or more of water;
• and
• (D) 0.1 mass % to 1.5 mass % of a nonionic surfactant, wherein, in the oral composition, the solubility of the compound represented by formula (I) is enhanced as compared to its solubility in a second composition that is the same as the oral composition except that the second composition lacks component (B), the cationic bactericide, and wherein (A)/(B), the mass ratio of the content of component (A) to the content of component (B), is 0.1 to 100.